ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

  • Views:

    Views Icon 1548
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023. 

More from this programme

About the episode

We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826).

This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that aficamten treatment was well-tolerated in patients with nHCM, supporting further study of the drug in a phase 3 trial. 

Interview Questions:

  1. What is currently understood about the pathophysiology of nHCM and what treatment options are available in 2023?
  2. How does Aficamten, a selective inhibitor of cardiac myosin, work?
  3. What was the study design, patient population, and outcome measures of REDWOOD-HCM-Cohort 4?
  4. What data was presented at the HFA  and what conclusions can be drawn from the findings?
  5. What safety considerations and adverse events were observed?
  6. What are the next steps in research or clinical development?

Faculty Biographies

Ahmad Masri

Ahmad Masri

Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.

He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.

View full profile


You must be to comment. If you are not registered, you can register here.